Ann: Zeliras diabetic nerve pain drug outperforms Lyrica, page-169

I agree that this stock is a unicorn. I’m not surprised at the wild fluctuations in price. What else is to be expected when the stock is under $5 and great news is announced? Of course it’d be a prime day trader target, and we’ll experience wild swings until the stock becomes too expensive to make day trading in this fashion worthwhile.

All they have to do is continue down this path. If successful, these wild swings will be a distant memory and those who have patiently held over the long haul will be generously rewarded.

I’m sticking to my guns on the GW Pharma comparison. If they did it, why can’t Zelira.